ID

23562

Beschrijving

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1); ODM derived from: https://clinicaltrials.gov/show/NCT00308139

Link

https://clinicaltrials.gov/show/NCT00308139

Trefwoorden

Versies (1)
  1. 09-07-17 09-07-17 -
Houder van rechten

Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.

Geüploaded op

9 juli 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type 2 Diabetes Mellitus NCT00308139

Engels

Eligibility Type 2 Diabetes Mellitus NCT00308139

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
Beschrijving

diabetes mellitus type 2 with diet modification, exercise, metformin, sulfonylureas, thiazolidinediones

Datatype

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0086153
UMLS CUI [1,3]
C0015259
UMLS CUI [1,4]
C0025598
UMLS CUI [1,5]
C3653359
UMLS CUI [1,6]
C1257987
hemoglobin a1c (hba1c) of 7.1% to 11.0%, inclusive, at screening.
Beschrijving

hba1c

Datatype

boolean

Alias
UMLS CUI [1]
C0019018
body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
Beschrijving

bmi

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
(for sub-study) currently participating in open ended assessment period of main study 2993 lar105
Beschrijving

study participation

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
has been previously exposed to exenatide (byetta®), exenatide lar, or any glucagon-like peptide-1 (glp-1) analog.
Beschrijving

exenatide, glucagon-like peptide 1

Datatype

boolean

Alias
UMLS CUI [1]
C0167117
UMLS CUI [2]
C0061355
received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
Beschrijving

investigational drug, study participation

Datatype

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2348568
has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
Beschrijving

excluded medications

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2828389
alpha glucosidase inhibitor or meglitinide within 30 days of screening;
Beschrijving

alpha glucosidase inhibitor, meglitinide

Datatype

boolean

Alias
UMLS CUI [1]
C3539108
UMLS CUI [2]
C0065880
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
Beschrijving

insulin

Datatype

boolean

Alias
UMLS CUI [1]
C0021641
regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
Beschrijving

gastrointestinal motility affecting drugs

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
Beschrijving

systemic corticosteroids

Datatype

boolean

Alias
UMLS CUI [1]
C2825233
regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
Beschrijving

addictive drugs

Datatype

boolean

Alias
UMLS CUI [1]
C0813966
prescription or over-the-counter weight loss medications within 6 months of screening.
Beschrijving

over-the-counter weight loss medication

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013231
UMLS CUI [1,2]
C0376606
(for sub-study) subjects will be terminated from study who do not participate in the dual chamber pen substudy
Beschrijving

study participation

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
Terug naar het begin van de pagina

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00308139

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
diabetes mellitus type 2 with diet modification, exercise, metformin, sulfonylureas, thiazolidinediones
Item
has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
boolean
C0011860 (UMLS CUI [1,1])
C0086153 (UMLS CUI [1,2])
C0015259 (UMLS CUI [1,3])
C0025598 (UMLS CUI [1,4])
C3653359 (UMLS CUI [1,5])
C1257987 (UMLS CUI [1,6])
hba1c
Item
hemoglobin a1c (hba1c) of 7.1% to 11.0%, inclusive, at screening.
boolean
C0019018 (UMLS CUI [1])
bmi
Item
body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
boolean
C1305855 (UMLS CUI [1])
study participation
Item
(for sub-study) currently participating in open ended assessment period of main study 2993 lar105
boolean
C2348568 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
exenatide, glucagon-like peptide 1
Item
has been previously exposed to exenatide (byetta®), exenatide lar, or any glucagon-like peptide-1 (glp-1) analog.
boolean
C0167117 (UMLS CUI [1])
C0061355 (UMLS CUI [2])
investigational drug, study participation
Item
received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
excluded medications
Item
has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
boolean
C0013227 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
alpha glucosidase inhibitor, meglitinide
Item
alpha glucosidase inhibitor or meglitinide within 30 days of screening;
boolean
C3539108 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
insulin
Item
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
boolean
C0021641 (UMLS CUI [1])
gastrointestinal motility affecting drugs
Item
regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
systemic corticosteroids
Item
regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
boolean
C2825233 (UMLS CUI [1])
addictive drugs
Item
regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
boolean
C0813966 (UMLS CUI [1])
over-the-counter weight loss medication
Item
prescription or over-the-counter weight loss medications within 6 months of screening.
boolean
C0013231 (UMLS CUI [1,1])
C0376606 (UMLS CUI [1,2])
study participation
Item
(for sub-study) subjects will be terminated from study who do not participate in the dual chamber pen substudy
boolean
C2348568 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial